Sven de Vos

16.6k total citations · 4 hit papers
192 papers, 7.6k citations indexed

About

Sven de Vos is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Sven de Vos has authored 192 papers receiving a total of 7.6k indexed citations (citations by other indexed papers that have themselves been cited), including 121 papers in Pathology and Forensic Medicine, 90 papers in Genetics and 90 papers in Oncology. Recurrent topics in Sven de Vos's work include Lymphoma Diagnosis and Treatment (114 papers), Chronic Lymphocytic Leukemia Research (87 papers) and CAR-T cell therapy research (58 papers). Sven de Vos is often cited by papers focused on Lymphoma Diagnosis and Treatment (114 papers), Chronic Lymphocytic Leukemia Research (87 papers) and CAR-T cell therapy research (58 papers). Sven de Vos collaborates with scholars based in United States, United Kingdom and France. Sven de Vos's co-authors include H. Phillip Koeffler, John P. Leonard, Dieter Hoelzer, Wolf‐K. Hofmann, Andres Forero‐Torres, Jeff P. Sharman, Stephen M. Ansell, Brad S. Kahl, Robert Chen and Kerry J. Savage and has published in prestigious journals such as The Lancet, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Sven de Vos

186 papers receiving 7.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

2012 1.0k citations Anas Younes, Ajay K. Gopal et al. Journal of Clinical Oncology profile →
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

2009 590 citations Sven de Vos et al. Blood profile →
Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

2006 553 citations Sven de Vos et al. Journal of Clinical Oncology profile →
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial

2022 186 citations Sattva S. Neelapu, Michael Dickinson et al. Nature Medicine profile →

Peers

Countries citing papers authored by Sven de Vos

Since Specialization

Citations

This map shows the geographic impact of Sven de Vos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sven de Vos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sven de Vos more than expected).

Fields of papers citing papers by Sven de Vos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sven de Vos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sven de Vos. The network helps show where Sven de Vos may publish in the future.

Co-authorship network of co-authors of Sven de Vos

This figure shows the co-authorship network connecting the top 25 collaborators of Sven de Vos. A scholar is included among the top collaborators of Sven de Vos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sven de Vos. Sven de Vos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies 2025 ·Journal of Clinical Oncology ·Frederick L. Locke, Javier Muñoz, Michael Tees, Lazaros J. Lekakis, Sven de Vos, Rajneesh Nath, Don A. Stevens, Shahbaz A. Malik, Geoffrey Shouse, Mehdi Hamadani, Olalekan O. Oluwole, Miguel‐Angel Perales, David B. Miklos, P.W. Fisher, Amy Feng, Lynn Navale, (unknown), Sattva S. Neelapu	11
2	Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study 2025 ·Blood ·Julio C. Chávez, Michael Dickinson, Javier Muñoz, Matthew L. Ulrickson, Catherine Thiéblemont, Olalekan O. Oluwole, Alex F. Herrera, Chaitra S. Ujjani, (unknown), Peter A. Riedell, Natasha Kekre, Sven de Vos, Jacob Wulff, (unknown), Joshua D. Winters, Ioana Kloos, Hairong Xu, Sattva S. Neelapu	3
3	ABCL-404: Epcoritamab + R-ICE in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Eligible For Autologous Stem Cell Transplantation (ASCT): EPCORE NHL-2 2025 ·Clinical Lymphoma Myeloma & Leukemia ·Marek Trněný, Raúl Córdoba, Sven de Vos, (unknown), Gerardo Musuraca, Justin Darrah, Eliza A. Hawkes, Daniel Morillo, Rogier Mous, Anna Sureda, Umberto Vitolo, Reid W. Merryman, Tony Jiang, (unknown), Liwei Wang, (unknown), Catherine Thieblemont, (unknown)	0
4	Epcoritamab + R-DHAX/C in transplant-eligible patients (pts) with high-risk relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). 2024 ·Journal of Clinical Oncology ·Yasmin Karimi, Pau Abrisqueta, Sven de Vos, Marcel Nijland, Fritz Offner, (unknown), (unknown), (unknown), (unknown), Raúl Córdoba, Lorenzo Falchi	7
5	Survival benefit of autologous transplant (ASCT) for mantle cell lymphoma (MCL) in the California Cancer Registry (CCR). 2024 ·Journal of Clinical Oncology ·(unknown), (unknown), John M. Timmerman, Patricia A. Young, Herbert Eradat, Sven de Vos, Sarah M. Larson, Monica Mead	0
6	ABCL-272 Epcoritamab + R-DHAX/C Induces Deep, Durable Responses in Transplant-Eligible Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL), Including High-Risk Disease 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Pau Abrisqueta, Lorenzo Falchi, Marcel Nijland, Sven de Vos, Fritz Offner, (unknown), (unknown), (unknown), (unknown), Yasmin Karimi, Raúl Córdoba	1
7	Fixed-Duration Epcoritamab + R2 Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: 2-Year Follow-up from Arm 2 of the Epcore NHL-2 Trial 2024 ·Blood ·Lorenzo Falchi, Anna Sureda, Sirpa Leppä, Joost S.P. Vermaat, Marcel Nijland, Jacob Haaber Christensen, Sven de Vos, Harald Holte, Reid W. Merryman, Pieternella J. Lugtenburg, (unknown), Kim Linton, (unknown), Christopher Morehouse, Andrew J. Steele, (unknown), Liwei Wang, Daniela Hoehn, Martin Hutchings, David Belada	5
8	Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7) 2023 ·Blood Cancer Discovery ·Simone Filosto, Saran Vardhanabhuti, Miguel Canales, Xavier Poiré, Lazaros J. Lekakis, Sven de Vos, Craig A. Portell, (unknown), (unknown), Marco Schupp, Soumya Poddar, (unknown), Carmen M. Warren, Ethan G. Aguilar, Justin A. Budka, (unknown), Justin Chou, Adrian Bot, Rhine R. Shen, Jason R. Westin	18
9	Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment 2023 ·Clinical Cancer Research ·Mark Roschewski, Manish R. Patel, Patrick M. Reagan, Nakhle S. Saba, Graham P. Collins, Hendrik‐Tobias Arkenau, Sven de Vos, Barrett Nuttall, Melih Acar, Kathleen A. Burke, (unknown), (unknown), Shringi Sharma, Brian Dougherty, Daniel Stetson, David F. Jenkins, Andrew Mortlock, (unknown), Veerendra Munugalavadla, Ian W. Flinn	13
10	HIGH COMPLETE METABOLIC RESPONSE RATES WITH EPCORITAMAB + R‐CHOP IN PREVIOUSLY UNTREATED (1L) HIGH‐RISK DLBCL, INCLUDING DOUBLE‐HIT/TRIPLE‐HIT: EPCORE NHL‐2 UPDATE 2023 ·Hematological Oncology ·Lorenzo Falchi, Michael Roost Clausen, Fritz Offner, Sven de Vos, Joshua Brody, Kim Linton, Sylvia Snauwaert, Raúl Córdoba, Jian Wu, (unknown), (unknown), (unknown), David Belada	2
11	Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial breakdown → 2022 ·Nature Medicine ·Sattva S. Neelapu, Michael Dickinson, Javier Muñoz, Matthew L. Ulrickson, Catherine Thiéblemont, Olalekan O. Oluwole, Alex F. Herrera, Chaitra S. Ujjani, Yi Lin, Peter A. Riedell, Natasha Kekre, Sven de Vos, Christine Lui, Francesca Milletti, Jinghui Dong, (unknown), Julio C. Chávez	186
12	Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody Tafasitamab in relapsed/refractory DLBCL 2021 ·SHILAP Revista de lepidopterología ·(unknown), Daria Gaut, Caspian Oliai, (unknown), Sven de Vos	8
13	The combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma 2020 ·British Journal of Haematology ·Nathan Fowler, Loretta J. Nastoupil, Sven de Vos, Mark Knapp, Ian W. Flinn, Robert Chen, Ranjana H. Advani, Sumeet Bhatia, Peter Martin, Raul Mena, R. Eric Davis, Sattva S. Neelapu, Karl Eckert, Jerry Ping, (unknown), Darrin M. Beaupre, Jutta K. Neuenburg, M. Lia Palomba	20
14	Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma 2012 ·Clinical Cancer Research ·Andres Forero‐Torres, Sven de Vos, Brad Pohlman, (unknown), Damien M. Cronier, Nam H. Dang, Susan P. Carpenter, Barrett W. Allan, (unknown), Christopher A. Slapak, Mitchell R. Smith, Brian K. Link, James E. Wooldridge, Kristen N. Ganjoo	54
15	Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma breakdown → 2012 ·Journal of Clinical Oncology ·Anas Younes, Ajay K. Gopal, Scott E. Smith, Stephen M. Ansell, Joseph D. Rosenblatt, Kerry J. Savage, Radhakrishnan Ramchandren, Nancy L. Bartlett, Bruce D. Cheson, Sven de Vos, Andres Forero‐Torres, Craig H. Moskowitz, Joseph M. Connors, Andreas Engert, Emily K. Larsen, Dana A. Kennedy, Eric L. Sievers, Robert Chen	1014
16	Effects of dietary wheat bran on absorption and accumulation of PCBs in rats 2007 ·Chemosphere ·(unknown), Sven de Vos, R. De Schrijver	4
17	Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray 2001 ·Blood ·Wolf‐K. Hofmann, Sven de Vos, Kunihiro Tsukasaki, William Wachsman, Geraldine S. Pinkus, Jonathan Said, H. Phillip Koeffler	150
18	Kaposiʼs sarcoma-associated herpesvirus/human herpesvirus type 8 encephalitis in HIV-positive and -negative individuals 1997 ·AIDS ·Jonathan W. Said, Taizo Tasaka, Sven de Vos, H. Phillip Koeffler	29
19	Effects of potent vitamin D3 analogs on clonal proliferation of human prostate cancer cell lines 1997 ·The Prostate ·Sven de Vos, Stuart Holden, David Heber, Elena Elstner, Lise Binderup, Milan R. Uskoković, (unknown), (unknown), Jennifer Lê, Steve K. Cho, H. Phillip Koeffler	35
20	Leukotriene B₄ transcriptionally activates interleukin‐6 expression involving NK‐xB and NF‐IL6 1992 ·European Journal of Immunology ·Marion A. Brach, Sven de Vos, Christian Arnold, (unknown), Roland Mertelsmann, F. Herrmann	96

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact